CPTx is pioneering immune-silent single-stranded DNA (ssDNA) vectors as a new foundation for in vivo CAR T therapies. Our ssDNA + LNP platform is redosable, tunable, and durable, a clear contrast to viral & nonviral vectors that permanently integrate and to mRNA approaches that fade too quickly for oncology.
We see broad potential for our in vivo CAR T platform for oncology, autoimmune diseases and beyond.
Traditional viral delivery methods and mRNA face well-known limitations, including the risk of immune activation, restrictions on payload size, lack of tissue specificity, and significant manufacturing complexity. Our in vivo CAR-T therapies avoid these limitations.
Built with ssDNA + non viral LNPs, our in vivo CAR-T therapies offer:
Immune-silent, repeatable dosing
Precise tissue and cell targeting
Scalable, modular manufacturing
Tunable and durable effect
While we are currently focused on oncology, our platform can be leveraged for a variety of in vivo gene therapies, offering modular control over:
We manufacture long, high-sequence-fidelity ssDNA constructs at research and clinical scale, serving CPTx and a growing network of partners.
Pharmaceutical and biotech companies come to us not only for product innovation — but also for our unique ability to build what others can’t. We welcome collaborations across research, clinical development, and advanced DNA manufacturing.
We invite you to explore how our precision DNA therapies can accelerate your breakthroughs.